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Nuclear genetic disorders causing mitochondrial DNA (mtDNA) depletion are clinically and genetically heterogeneous, and the
molecular etiology remains undiagnosed in the majority of cases. Through whole-exome sequencing, we identified recessive nonsense
and splicing mutations in FBXL4 segregating in three unrelated consanguineous kindreds in which affected children present with a
fatal encephalopathy, lactic acidosis, and severe mtDNA depletion in muscle. We show that FBXL4 is an F-box protein that colocalizes
with mitochondria and that loss-of-function and splice mutations in this protein result in a severe respiratory chain deficiency, loss
of mitochondrial membrane potential, and a disturbance of the dynamicmitochondrial network and nucleoid distribution in fibroblasts
from affected individuals. Expression of the wild-type FBXL4 transcript in cell lines from two subjects fully rescued the levels of
mtDNA copy number, leading to a correction of the mitochondrial biochemical deficit. Together our data demonstrate that mutations
in FBXL4 are disease causing and establish FBXL4 as a mitochondrial protein with a possible role in maintaining mtDNA integrity and
stability.Introduction
Pediatric-onset mitochondrial disease has an estimated
incidence of 1 in 5,000,1 but despite this common occur-
rence the molecular etiology in individual cases often
remains unknown. Mitochondria play a key role in a va-
riety of fundamental cellular processes including oxida-
tive phosphorylation (OXPHOS), essential metabolic
pathways, apoptosis, and calcium buffering. Mitochon-
dria have a unique bigenomic heritage, and their proper
functioning is consequently dependent upon the coordi-
nated expression and interaction of both nuclear and
mitochondrial-encoded gene products.2 More than
1,000 nuclear genes play a role in mitochondrial func-
tion,3 giving rise to a potential for extensive genetic
heterogeneity in the primary mitochondrial disease pop-
ulation. Most cases are therefore probably caused by
nuclear-encoded mutations, with autosomal-recessive
transmission being most commonly observed.1,4 Clinical
presentation varies widely and can involve multiple
organ systems, often triggering extensive diagnostic in-
vestigations that result in a molecular diagnosis for a mi-
nority of individuals.
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. Open access uDNA (mtDNA), ultimately leading to secondary mtDNA
abnormalities in clinically affected tissues. Damage to
mtDNA manifests in two molecularly distinct forms: the
accumulation of clonally expandedmtDNA deletions asso-
ciated with focal respiratory-deficient cells and a quantita-
tive loss of mtDNA copy number that is characteristic of
mtDNA depletion syndromes. Multiple mtDNA deletion
disorders typically manifest in adulthood,5 whereas
mtDNA depletion disorders are usually very severe, early-
onset diseases of childhood characterized by isolated organ
or multisystem involvement.6 With the exception of
MPV17 whose function remains unknown,7 the products
of identified candidate genes are involved in either mtDNA
replication/repair or the maintenance of mitochondrial
deoxyribonucleotide pools required for faithful mtDNA
synthesis.1,3
Here, we report the finding of mutations in
FBXL4 (MIM 605654), which encodes an orphan F-box
protein, identified in affected children from three
unrelated families with multiple mitochondrial respira-
tory chain defects and mtDNA depletion. Moreover,
we provide evidence that mutations in this gene cause
defective mtDNA maintenance resulting in extensive
mitochondrial dysfunction leading to severe enceph-
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Material and Methods
Subjects
Informed consent for diagnostic and research studies was obtained
for all subjects or their parents and for 204 healthy, ethnically
matched anonymized Arabian controls in accordance with the
Declaration of Helsinki protocols and approved by local Institu-
tional Review Boards. Genomic DNA was extracted from periph-
eral-blood lymphocytes, skeletal muscle, fibroblasts, and/or saliva
according to standard protocols.
Muscle Histology and Respiratory Chain Activity
Assays
Routine histological staining and histochemical reactions of
oxidative enzyme activities including cytochrome c oxidase
(COX) were performed on fresh-frozen sections (10 mm) of muscle
according to established protocols.8 The activities of the individ-
ual respiratory chain complexes I–IV were measured in skeletal
muscle homogenates and cultured fibroblasts as described previ-
ously9 and activities expressed relative to that of citrate synthase
(a matrix marker enzyme) for the muscle, or relative to mitochon-
drial protein for the cells, and expressed as a percentage of normal
controls.
Identification and Validation of Pathogenic FBXL4
Mutations
Initial molecular studies involved the exclusion of large-scale
mtDNA rearrangements by long-range PCR,10 sequencing of the
entire mitochondrial genome (ABI 3130xl, Applied Biosystems)
essentially as described,11,12 and the assessment of mtDNA copy
number in muscle.13
Exonic sequences were targeted and enriched from genomic
DNA with the Agilent SureSelect Human exome kit (subject 1
[S1]) and sequenced on an Illumina Genome Analyzer IIx.
Whole-exome sequencing was conducted on subject 2 (S2) and
subject 3 (S3) with a custom capture design called ‘‘VCROME’’
developed at the BCM Human Genome Sequencing Center that
enriches for approximately 20,000 genes comprising a total of
45 Mb of captured genomic sequence.14 Samples were sequenced
in a paired-end strategy on an Illumina HiSeq 2000 instrument.
Sequence data alignments were performed to human reference
sequence hg19 (UCSC Genome Browser) by BWA software.15
Duplicate reads were removed with the Picard program. Recalibra-
tion and realignment of the data were accomplished with the
Genome Analysis Toolkit (GATK).16,17 Single-nucleotide variants
(SNVs) and small insertions and deletions (indels) were called by
GATK. Quality control filtering of variants was based on coverage,
strand bias, mapping quality, and base quality. Annotation of
variants was conducted with internally developed Perl scripts. Pre-
diction for potential functional consequences of variants was
conducted with SIFT18 and PolyPhen2.19 The evolutionary conser-
vation of missense mutations was determined by genomic evolu-
tionary rate profiling (GERP), which approximates evolutionary
constraint at a locus by maximum likelihood estimation,20,21
and PhyloP, which predicts departures from the neutral evolu-
tion,22 and the reported score is the result of analysis of an align-
ment of 46 different placental mammal species. The range of
scores is from 13.9 (minimum) to 2.9 (maximum) with
mean ¼ 0.03. The GERPþþ score reported here is based on the
alignment of 35 mammalian species and the maximum GERP
score for this analysis is 6.18.472 The American Journal of Human Genetics 93, 471–481, SeptembOrthogonal validation of FBXL4 mutations was completed for
each propositus, and recessive segregation was confirmed with
PCR-based Sanger sequencing with the following primer pairs
(FBXL4 GenBank accession number NM_012160.3): S1_Fwd
50-TGTAAAACGACGGCCAGTAACAGTTTGCATGTCTGAGCA-30
and S1_Rev 50-CAGGAAACAGCTATGACCAAACCAAGCCATCT
TATCAGGA-30; S2_Fwd 50-GCTTACCTCAACCAACGCTTA-30 and
S2_Rev 50-GCCTTGAATTGTCTTGCAGC-30; and S3_Fwd 50-
CTGCGAACAGAAGGACACATC-30 and S3_Rev 50-GTCCTAGAT
GCTAAATTGGCTGG-30. Each of the FBXL4mutations was further
investigated in 204 ethnically matched healthy Arab controls by
direct Sanger sequencing across the mutation site.
Determination of mtDNA Copy Number in Tissues
In addition to testingmuscle mtDNA copy number,13 this was also
determined in cultured fibroblasts by real-time qPCR essentially as
described previously23,24 with beta-2 microglobulin (B2M) as the
nuclear gene (nDNA) normalizer for the calculation of mtDNA/
nDNA ratio. The ND1 region of human mtDNA was amplified
with forward primer 50-GTCAACCTCGCTTCCCCACCCT-30 and
reverse primer 50-TCCTGCGAATAGGCTTCCGGCT-30. A fragment
of human B2M was amplified with forward primer 50-CGACGG
GAGGGTCGGGACAA-30 and reverse primer 50-GCCCCGCGAAA
GAGCGGAAG-30. The PCR reaction was conducted (in triplicate)
on total genomic DNA and utilized iTaqTM SYBR Green Supermix
with ROX (Bio-Rad Laboratories).
qRT-PCR
RNA was extracted from confluent cells with TRIzol reagent (Life
Technologies) according to manufacturer instructions, treated
with RQ1 RNase-free DNase, and purified with PureLink RNA
mini kit (Life Technologies). Synthesis of cDNA was performed
with SuperScript III (Life Technologies) and oligodT according to
manufacturer instructions. Quantitative real-time PCR experi-
ments were performed with a StepOne Plus RT-PCR system
(Applied Biosystems), RT2 qPCR Primer Assays for HumanGAPDH
and FBXL4 (SABiosciences), and PerfeCTa SYBR Green FastMix
ROX (Quanta Biosciences).
Oligodeoxynucleotide primers and dual-labeled probes to detect
either spliced or unspliced forms of FBXL4were as follows: FBXL4-
unspliced_Fwd, 50-GCAGTGTCACAGTAGTTA-30; FBXL4-unsplice-
d_Rev, 50-ACCTGAATCTTGCCAATA-30; FBXL4-unspliced_Probe,
50-CCACTATCTTCATTCCTACCTCCTACC-30; FBXL4-spliced_Fwd,
50-GACACAGACATTGATGAA-30; FBXL4-spliced_Rev, 50-GGAG
TTTTCTTAAGGATGC-30; and FBXL4-spliced_Probe, 50-ACCATTC
TTGTTCCTAATATGTCCAGC-30. The cycle of threshold value
(Ct) was normalized to the transcripts for the housekeeping gene
GAPDH. All assays were conducted in triplicate and the results
are shown as the average and standard deviation.
Bioinformatic Analysis of the FBXL4 Protein
Protein structure modeling was conducted with the Phyre2 server
with the 3D structure image realized by JMOL.25 Mitochondrial
localization signal prediction was determined with MitoProt.26
Conserved domains were determined with NCBI Conserved
Domain Database (CDD).27
Fibroblast Cell Culture
Fibroblasts from two affected individuals (S1 and S2) and age-
matched controls were grown in MEM (Life Technologies) supple-
mented with FBS to 10%, 13 MEM vitamins, 2 mM L-glutamine,er 5, 2013
1 mM sodium pyruvate, 13 penicillin/streptomycin, 13 nones-
sential amino acids, and 0.41 mM uridine. Cells were maintained
as a monolayer in a humidified 37C, 5% CO2 atmosphere.
Investigation of Mitochondrial and Nucleoid
Morphology
Fibroblasts were grown in 35 mm imaging dishes (iBIDI, Thistle
Scientific) to 70%–80% confluency. Cells were incubated at 37C
in the growth media described above, supplemented with either
3 ml of PicoGreen (Invitrogen) for 45 min or with 100 nM Mito-
Tracker Red (Invitrogen) for 25min. Cells were washed in standard
media and imaging performed with a 633 oil immersion lens on
the inverted Axiovert 200M (Zeiss), with shutter speeds of
200 ms and 75 ms for MitoTracker Red and PicoGreen, respec-
tively.
Assessment of Mitochondrial Membrane Potential
Mitochondrial membrane potential was assessed with MitoProbe
DilC1(5) Assay kit for Flow Cytometry (Life Technologies)
following general manufacturer recommendations with some
modifications. In brief, confluent cells were harvested and
counted with Vi-CELL cell viability analyzer (Beckman Coulter).
The cells were either stained directly with 50 nM DilC1(5) dye
for 30 min at 37C, 5% CO2, or preincubated with 50 mM
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) for 15 min
at 37C, 5% CO2 prior to staining with DilC1(5). Cells were
analyzed on a flow cytometer with 633 nm excitation. Results
are reported as the difference between the mean fluorescence in-
tensity (MFI) of cells treated with CCCP or not. All assays were
conducted in triplicate and shown as the average and standard
deviation.
Microscale Oxygraphy Analysis
Mitochondrial respiratory activity was measured in live fibroblasts
by microscale oxygraphy analysis with the Seahorse Biosciences
XF24 Analyzer (Seahorse Biosciences). Cells were seeded onto 24-
well plates at a density of 30,000 cells/well and prior to performing
the experiment, the growth media was replaced with basic media
supplemented with FBS to 3%, 10 mM pyruvate, 2 mM L-gluta-
mine, and 1 mg/ml glucose and the cells incubated in a CO2-free
atmosphere. Measurements of O2 consumption rate (OCR) and
proton production rate (PPR) were taken at regular intervals while
the following compounds were injected to test mitochondrial
activity: oligomycin (to 1.3 mM) to block the ATP synthase, two
sequential additions of carbonyl cyanide p-trifluoromethoxy-phe-
nylhydrazone (FCCP), a respiratory chain uncoupler to drive
maximum respiratory capacity (first to 2 mM, then to 3 mM), and
antimycin (to 2.5 mM), which blocks Complex III.28
Data were normalized by cell number, and a number of param-
eters assessed,29 subsequent to the subtraction of nonmitochon-
drial respiration (NMR) from each value. ATP production by
OXPHOS was calculated by multiplying ATP turnover ((basal
OCR – NMR) – (oligomycin-inhibited OCR – NMR)) by the estab-
lished phosphorus/oxygen (P/O) ratio of 2.3.30 ATP production by
glycolysis is considered to have a 1:1 ratio with lactate production,
which is measured by PPR.31 Spare respiratory capacity ¼
((maximal OCR – NMR) – (basal OCR – NMR)), whereas ATP
coupling efficiency ¼ ((basal OCR – NMR) – (oligmycin-inhibited
OCR)) / basal OCR 3 100). Five separate control cell lines under-
went multiple testing (n R 10) and the means were combined
to calculate control data (mean 5 SD; n ¼ 5). Cell lines fromThe Americaneach subject were also tested multiple times (n R 10). An un-
paired, two-tailed Student’s t test was performed to determine
the significance of any differences between the data sets and p
values were considered significant at the 95% confidence interval.
Immunoblotting
Total cellular protein was extracted, size-separated on 12% gels by
SDS-PAGE, and transferred to a methanol-activated PVDF mem-
brane. Immunoblotting was performed with primary antibodies
from Abcam (NDUFA9, NDUFB8, NDUFA13, SDHA, UQCRC2,
MTCOI, MTCOII, COXIV, ATPB, and TOMM20) and Sigma
(b-actin). Chemiluminescent detection of the bands was achieved
with the Amersham ECL Prime Kit (GE Healthcare) for signal
development, according to the manufacturer’s instructions, and
the membrane was viewed with the ChemiDocMP Imaging
System (Bio-Rad).
Gene Rescue Studies
Fibroblasts from subjects and controls were stably infected with a
pLX302 lentiviral mammalian expression vector system express-
ing EGFP and FBXL4 cDNA (NM_012160.3). HEK293 cells were
plated in DMEM (Hyclone) with 10% FBS (Atlanta Biologicals)
and transfected with pLX302-EGFP/pLX302-FBXL4 in Opti-MEM
medium I (Life Technologies) and the packaging mix (5 mg
pMDLg/pRRE, 2.5 mg RSV-rev, and 3 mgMD2.VSVG) with Lipofect-
amine 2000 (Life Technologies). Infectious lentiviral supernatant
was collected at 48 and 60 hr, filtered, and used to infect growing
fibroblasts with 8 mg/ml polybrene (Sigma) before selection by pu-
romycin (1.25 mg/ml).
Mitochondrial Localization Studies of the FBXL4
Protein
Healthy control fibroblasts were infected with pBabe vector con-
taining HA-tagged FBXL4 cDNA (NM_012160.3) and selected
with puromycin (1.25 mg/ml). Noninfected cells and HA-FBXL4-
expressing cells were seeded on a micro-Slide VI flat ibiTreat
microscopy chamber (Ibidi) at 50%–60% confluence. Cells were
incubated for 10 min in normal growth medium containing
100 nM MitoTracker Red CMXRos (Molecular Probes) and fixed
with 4% paraformaldehyde. Cells were permeabilized by incuba-
tion in 0.1% Triton X-100 and blocked in 10% normal goat serum.
Fluorescent staining was performed with mouse anti-HA primary
antibody (Cell Signaling) and AlexaFluor 488 goat anti-mouse
secondary antibody (Life Technologies). Cells were counterstained
in Vectashield mountingmediumwith DAPI (Vector Laboratories)
and visualized at 1003 magnification with a Nikon Eclipse 90i
microscope. The images were processed with NIS-elements v.3.0
software.Results
Mutations in FBXL4 Identified in Individuals with
Encephalopathy and Persistent Lactic Acidosis
Detailed descriptions of the three families (all of Arabian
origin) and affected cases studied are provided in Table 1.
Subject 1 (S1) presented with delayed milestones and brain
atrophy by CT at the age of 3 months, which worsened by
14 months to include severe psychomotor delay, poor
growth, and persistent lactic acidosis. This individual
died of encephalopathy at the age of 3 years, 9 months.Journal of Human Genetics 93, 471–481, September 5, 2013 473
Table 1. Clinical Presentation of Affected Children from Three Families
Subject
Birth
Weight
(Gestation)
Dysmorphic
Features Microcephaly
Dev.
Delay Tone
Eye
Disease Cranial MRI
Lactic
Acidosis Elevated
Blood
Ammonia
Age at
DeathY/N Onset
S1
(family 1,
V-11)
1.5 kg (T) none congenital;
<3rd centile
global normal no generalized
cerebral atrophy
Y 14
months
no 3 years
9 months
V-8
(family 1)
2.5 kg (T) none congenital;
<3rd centile
global low no normal Y birth yes 1 year
8 months
V-3
(family 1)
2.3 kg (T) yes
(craniofacial)
acquired;
<3rd centile
at 2 years
global low congenital
cataracts
dilated ventricles,
hypoplastic left
hemisphere and
cerebellar vermis
Y 4 months no 2 years
V-4
(family 1)
2.2 kg (T) none no no low not
checked
not done Y birth yes 3 days
IV-5
(family 1)
unknown unknown unknown yes unknown unknown unknown Y birth unknown 4 years
S2
(family 2)
2.3 kg (T) yes
(craniofacial)
no global low cataracts,
OA
abnormal dorsal
brainstem and
post limb of IC,
prominent CM
Y birth no 4 months
S3
(family 3)
2.6 kg (T) yes
(craniofacial)
unknown global low no generalized atrophy,
delayed myelination,
abnormal signal in
BG and brainstem
Y 6 years unknown alive at
6 years
Abbreviations are as follows: BG, basal ganglia; CM, cisterna magna; Dev delay, developmental delay; IC, internal capsule; OA, optic atrophy; T, term (>37 weeks
<41 weeks).The extended family of S1 is significant for consanguinity
and includes four similarly affected children (Figure 1A,
Table 1). In order to elucidate the molecular basis of this
fatal encephalopathy and severe lactic acidosis, we per-
formed whole-exome sequencing in S1 (Figure 1A, subject
IV-11). Identified variants were prioritized as being likely
disease-causing mutations by a recessive model of inheri-
tance, population allele frequency of <0.001, and poten-
tial for damaging protein function and evolutionary
conservation. We identified a potentially pathogenic trun-
catingmutation (FBXL4 c.1555C>T [p.Gln519*]) in FBXL4
(GenBank accession number NM_012160.3), which
encodes an F-box and leucine-rich repeat (LRR) protein.
The homozygous c.1555C>T (p.Gln519*) mutation occurs
in the C-terminal LRR domain, which provides substrate
interaction and specificity for FBXL proteins (Figure 2A).
This variant was not observed by the 1000 Genomes
Project or the NHLBI Exome Sequencing Project. Impor-
tantly, it was shown to be absent from a panel of 408 ethni-
cally matched control chromosomes. The c.1555C>T
(p.Gln519*) mutation showed complete segregation with
the disease phenotype in all clinically affected family
members (Figure 1A: III-5, IV-3, IV-4, IV-8, and IV-11); all
parents were heterozygous carriers and unaffected children
available for genetic screening (Figure 1A: IV-1, IV-2, and
IV-7) were either carriers or did not harbor the mutation.
Two additional, unrelated individuals presenting with
similar symptoms early in life were subsequently subjected
to whole-exome sequencing, revealing additional muta-
tions in FBXL4. Subject 2 (S2) presented in the first month474 The American Journal of Human Genetics 93, 471–481, Septembof life with severe hypotonia, encephalopathy, cardiomy-
opathy, and lactic acidosis (serum lactate 18 mmol/l;
normal control range 0.7–2.1 mmol/l), leading to death
at age 4 months (Table 1). Three older siblings presented
with a similar fatal, early-onset phenotype, and the
proband’s mother has also suffered three miscarriages
(Figure 1B). Exome sequencing revealed that S2 was homo-
zygous for a different nonsense mutation in FBXL4
(c.1303C>T [p.Arg435*]), predicting an earlier truncation
of the protein than that observed in S1.
Subject 3 (S3) is a 6-year-old boy with a similar but less
severe clinical presentation (Table 1). Born to consanguin-
eous parents (Figure 1C), he has a history of severe intellec-
tual disability, global developmental delay, hypotonia,
poor growth, and persistent lactic acidosis. Imaging of
the brain by magnetic resonance imaging (MRI) without
contrast demonstrated global volume loss particularly the
subcortical and periventricular white matter with sig-
nificant abnormal signal in bilateral basal ganglia and
brainstem with associated delayed myelination. Magnetic
resonance spectroscopy of the brain demonstrated an
elevated lactate peak. S3 is homozygous for a missense
mutation (FBXL4 c.1703G>C) in the first base of the last
exon, which we demonstrated affects the splicing of this
exon (Figure 2C).
The FBXL4 mutations identified in S2 and S3 were also
determined to be absent from 408 ethnically matched
(Arabian) control chromosomes. Neither mutation was
present in the 1000 Genomes Project database. The
c.1303C>T (p.Arg435*) mutation found in S2 waser 5, 2013
Figure 1. Genetic Investigation of the Families Confirms Segregation with Disease of Recessive FBXL4 Mutations
The pedigrees of S1 (A), S2 (B), and S3 (C) are shown, highlighting the consanguineous nature of each family. The probands are indicated
by black arrows, and all individuals presenting with similar clinical features are shown as filled black symbols (pedigrees are drawn to
accepted standards37). A sequencing chromatogram obtained by targeted resequencing is shown for each proband, confirming the pres-
ence of the c.1555C>T (p.Gln519*) (S1), c.1303C>T (p.Arg435*) (S2), and c.1703G>CGC (S3) mutations.observed in 1/13,005 chromosomes sequenced by the
NHLBI Exome Sequencing Project. Familial segregation
of the recessive mutations was clearly demonstrated
(Figure 1).
FBXL4 Is a LRR F-Box Protein that Localizes to the
Mitochondria
Computational analysis of the protein structure of FBXL4
revealed canonical features of a LRR F-box protein with a
possible mitochondrial localization. Three-dimensional
structural modeling and searches for conserved sequence
domains elucidated the presence of the F-box and
AMN1 domains in the C-terminal portion of the protein
(Figures 2A and 2B). The second half of the protein
containing the F-box and AMN1 domains (amino acids
280–600) showed 23% identity to SKP2. At least nine
LRRs were clearly identified and an additional LRR
may also exist although this could not be concluded
with high confidence because of some disorder in the
model. No conserved domains were identified in the
N-terminal half of the protein. However, sequence ana-
lysis revealed a N-terminal mitochondrial localizationThe Americansignal (Figure 2A), the functionality of which was authen-
ticated through immunolocalization studies that showed
HA-tagged FBXL4 colocalizing with MitoTracker Red-
labeled mitochondria (Figure 2D).
Skeletal Muscle and Fibroblasts from Individuals with
FBXL4Mutations Show Combined Respiratory Chain
Deficiencies
The index cases from all three families showed significant
evidence of mitochondrial respiratory chain abnormalities
in diagnostic muscle biopsies. Histological and histo-
chemical analyses in S1 and S2 revealed evidence of respi-
ratory chain deficiency, with decreased reactivity for COX
histochemical activity in both cases (Figure 3A); in the
example of S1, those fibers that show COX activity unusu-
ally have discrete, punctate activity in the sarcoplasm.
Modified Gomori Trichrome staining revealed mild subsar-
colemmal accumulations in both cases (data not shown),
and the skeletal muscle biopsy of S3 revealed mild varia-
tion in fiber size, type 2 fiber predominance, a few fibers
with slight increase in glycogen content, and occasional
enlarged mitochondria on electron microscopy.Journal of Human Genetics 93, 471–481, September 5, 2013 475
Figure 2. FBXL4 Protein Structure and Localization
(A) Schematic of FBXL4 showing the location of the bioinformatically determined mitochondrial localization sequence (mt) and
conserved domains (F-box CDD ID pfam12937, AMN1 CDD ID cd09293). The locations of each of the mutations are indicated.
(B) Three-dimensional structural modeling of FBXL4 shows the canonical folds of the F-box and nine leucine-rich repeats. The protein
schematic and 3D structure are both displayed in reverse rainbow from the N to C terminus.
(C) Splicing of exon 9 was demonstrated to be significantly impaired in S3 compared to controls. Error bars indicate standard deviation;
***p < 0.0001.
(D) FBXL4 was confirmed to be a mitochondrial protein through an immunolocalization study in human fibroblasts, showing HA-
tagged FBXL4 (green) colocalizing with MitoTracker Red-labeled mitochondria. Nuclei were counterstained with DAPI (blue).A profound, combined respiratory chain defect was
confirmed in the muscle of S2 (Figure 3B), showing mark-
edly decreased activities of complexes I, III, and IV with
sparing of complex II activity. The biochemical defects
were less pronounced in S1 and S3 although complex IV
activity was ~60% of control values in both cases when
related to citrate synthase activity (Figure 3B), a finding
recapitulated in the direct measurement of respiratory
chain complex activities in fibroblast cell lines
(Figure 3C), which also all showed significantly (p <
0.0001) decreased mitochondrial membrane potential
(Figure 3D). There was a suggestion that citrate synthase
activity was decreased in the muscle from S1, thereby
explaining why the relative OXPHOS activity defects
were less pronounced and implying that FBXL4mutations
may affect the activities of other mitochondrial enzymes
apart from those containing mtDNA-encoded subunits
(data not shown).
Microscale oxygraphy in fibroblasts from S1 (c.1555C>T
[p.Gln519*]) and S2 (c.1303C>T [p.Arg435*]) provided476 The American Journal of Human Genetics 93, 471–481, Septembadditional evidence of a severe dysfunction of mitochon-
drial respiration (Figure 4A). Basal OCR and maximal
OCR were both significantly reduced in S1 (p ¼ 0.0012)
and S2 (p ¼ 0.0005). The reduced basal respiration in
both individuals resulted in reduced synthesis of ATP by
OXPHOS (Figure 4B) in comparison to controls (p <
0.001); to compensate for this loss, the amount of ATP
produced by glycolysis (Figure 4B) in fibroblasts from
affected individuals is increased (p < 0.01). The spare
respiratory capacity of fibroblasts from S1 and S2 are
significantly reduced in comparison to controls (p <
0.0001), suggesting that the mitochondria are working at
near-maximal capacity, with little capability to respond
to increased energy demand or stress (Figure 4C). The effi-
ciency of the coupling of respiration and ATP synthesis was
also significantly impaired in fibroblasts from S2
(p < 0.0001), indicating increased proton leak across the
membrane (Figure 4D). Fibroblasts from S1 showed normal
ATP coupling. Additionally, the steady-state levels of
subunits from respiratory chain complexes containinger 5, 2013
Figure 3. Individuals with FBXL4 Mutations Display Mitochondrial Biochemical Dysfunction
(A) Cytochrome c oxidase (COX) histocytochemical activities in skeletal muscle from S1 and S2 are globally decreased in comparison
to control muscle, although somewhat unusually there are occasional, COX-positive fibers in S1 showing discrete, punctate enzyme
activity.
(B and C) Respiratory chain complex biochemical activity was determined in both skeletal muscle (B) and fibroblasts (C) from all pro-
bands (dark gray columns, S1; light gray columns, S2; white columns, S3) and is shown relative to the mean activity measured in 25
controls.
(D) Mitochondrial membrane potential wasmeasured in fibroblasts from S1, S2, and S3 together with seven controls (C). Cells from each
affected individual showed severely compromised membrane potential compared to controls. ***p < 0.0001.
(E) Severe depletion ofmtDNAwas determined in skeletalmuscle and fibroblasts from each of the three probands (dark gray columns, S1;
light gray columns, S2; white columns, S3) whenmeasured in comparison to age-matched controlmuscle (n¼ 20) and fibroblasts (n¼ 3)
(black columns).
For all data, error bars indicate standard deviation.mtDNA-encoded subunits were found to be significantly
decreased in fibroblasts from both S1 and S2 (Figure 4E),
with the suggestion in S2 that expression of complex II
subunits (SDHA) were affected; the severity of this loss of
protein expression in the two fibroblast cell lines appear
to reflect the location of the FBXL4 truncating mutation.
The mitochondrial marker TOMM20 was unchanged in
patient fibroblasts, confirming normal mitochondrial pro-
tein content, thereby highlighting a specific problem with
OXPHOS subunit biogenesis.
Skeletal Muscle and Fibroblasts from Individuals with
FBXL4Mutations Show Severe mtDNA Depletion and
Disruption of Mitochondrial Morphology
Analysis of mtDNA copy number (Figure 3E) in skeletal
muscle by qPCR demonstrated severe mtDNA depletion
in S1 (~30% of control), S2 (<10% of control), and S3
(25% of control), leading to the observed biochemical
defects. This quantitative loss of mtDNA copy number
was recapitulated in the fibroblasts (Figure 3E), with S1
(45% of control), S2 (17% of control), and S3 (30% of con-
trol) all showing evidence of mtDNA depletion.The AmericanWe next investigated the mitochondrial morphology
in cells to determine whether this was disturbed as docu-
mented in other mtDNA maintenance disorders. Ass-
essment of the dynamic mitochondrial network and
distribution of nucleoids in fibroblasts from both S1 and
S2 revealed dramatic fragmentation and shortening of
mitochondria when compared to controls (Figure 5, top).
Nucleoids were enlarged and showed distinct perinuclear
clustering in both cell lines compared to smaller more
evenly distributed nucleoids within control cells (Figure 5,
bottom).
Delivery of Wild-Type FBXL4 to S1 and S2 Cells
Rescues mtDNA Copy Number and Biochemical
Defects
To verify that the mitochondrial respiratory chain defects
and quantitative loss of mtDNA copy number observed
in fibroblasts were due to loss of FBXL4 function, we
conducted gene rescue experiments wherein either a
wild-type copy of FBXL4 or a negative control (EGFP)
was virally delivered into cells from affected individuals
(S1 and S2). Previous profiling of mitochondrial functionJournal of Human Genetics 93, 471–481, September 5, 2013 477
Figure 4. Characterization of the OXPHOS Defects in Fibroblasts
(A) Microscale oxygraphy analysis of live fibroblasts demonstrated a profound respiratory deficiency in cells from both S1 (c.1555C>T
[p.Gln519*], n ¼ 22, white triangles) and S2 (c.1303C>T [p.Arg435*], n ¼ 14, white circles), compared to the combined data of control
cell lines (n ¼ 5, black squares). Error bars indicate the standard deviation.
(B) The total amount of ATP produced by fibroblasts from S1 and S2 is not dramatically different to controls, but the proportion contrib-
uted by OXPHOS (black columns) is significantly reduced, whereas that contributed by glycolysis (white columns) is significantly
increased.
(C) The ability of fibroblasts from S1 and S2 to respond to stress, as measured by the spare respiratory capacity (maximal OCRminus basal
OCR), is significantly reduced in comparison to controls. ***p < 0.0001.
(D) The efficiency of the coupling of respiration to ATP synthesis (oligomycin-sensitive OCR as a percent of basal OCR) was significantly
impaired in fibroblasts from S2 but not S1 compared to controls. For all data, error bars indicate standard deviation. ***p < 0.0001; NS,
not significant.
(E) Immunoblotting for protein components of each of the mitochondrial respiratory chain complexes was completed in S1 and S2 to
determine their abundance relative to control (labeled C). Three subunits of complex I (NDUFA13, NDUFB8, and NDUFA9), one of com-
plex II (SDHA), one of complex III (UQCRC2), three of complex IV (COXI, COXII, and COXIV), and one of complex V (ATPB) were
probed, with TOMM20 as a mitochondrial marker and b-actin as a loading control.in FXBL4 mutant fibroblasts had identified decreased
complex IV deficiency, membrane potential, and mtDNA
depletion (Figures 3C–3E). S1 and S2 cells expressing GFP
showed no significant improvement in these cellular
phenotypes (Figures 6A–6C). In contrast, cells from
both S1 and S2 expressing wild-type FBXL4 demon-
strated full rescue of mtDNA levels (p < 0.0001), complex
IV biochemical activity (p < 0.01), and membrane po-
tential (p < 0.0001) (Figures 6A–6C, respectively). In
addition, control fibroblasts stably expressing FBXL4
demonstrated that FBXL4 mRNA levels similar to those
in transformed cells from affected individuals
(Figure 6D) showed no difference in mtDNA copy num-
ber or membrane potential, demonstrating that FBXL4
overexpression itself does not cause an increase in
mtDNA copy number or biochemical activity (Figure 6).
These data provide unequivocal evidence that auto-478 The American Journal of Human Genetics 93, 471–481, Septembsomal-recessive FBXL4 mutations cause a quantitative
loss of mtDNA copy number and associated OXPHOS
activity defects in humans.Discussion
We present the clinical, molecular, and functional investi-
gation of multiple subjects from three unrelated families
all of Arabian origin with combined OXPHOS deficiency
resulting from severe mtDNA depletion. By combining
whole-exome sequencing with profiling of mitochondrial
function and gene rescue studies in cells from affected in-
dividuals, we identified and validated three independent,
pathogenic alleles in the orphan F-box protein FBXL4
which, to our knowledge, has not previously been associ-
ated with human disease.er 5, 2013
Figure 5. Mitochondrial Network and
NucleoidMorphology Is Disrupted in Indi-
viduals with FBXL4 Mutations
The upper panels show representative im-
ages of MitoTracker Red staining of control
(left), S1 (middle), and S2 (right) fibro-
blasts. Note fragmentation and shortening
of mitochondria in both these cell lines
compared to the control. The lower panels
show nucleoid staining by PicoGreen,
revealing larger nucleoids with perinuclear
clustering in cells from both subjects.We present overwhelming evidence in support of FBXL4
mutations causing a severe respiratory chain deficiency
resulting from dysregulation of mtDNA maintenance.
Affected individuals with different FBXL4 mutations
display a highly overlapping clinical presentation with
onset in the first years of life. Molecular analysis of tissues
identified a common pattern of decreased mtDNA copy
number and loss of mitochondrial membrane potential
in cells. Furthermore, a severe mitochondrial respiratory
deficiency was demonstrated in fibroblasts by microscale
oxygraphy and immunoblotting of respiratory chain pro-
teins. Key evidence supporting the pathogenic role of
mutations in FBXL4was demonstrated through functional
studies showing rescue of mtDNA copy number, biochem-
ical activity, and membrane potential in cells from two
affected individuals with different mutations transduced
with wild-type FBXL4.
There are some notable differences among subjects’ clin-
ical and molecular phenotypes that are presumably linked
to the severity of the causative FBXL4 mutation. Both S1
and S2, who have nonsense mutations, died within the
first 2 years of life. In contrast, S3, who has a missense
mutation that affects splicing of the last exon, although
severely affected with psychomotor retardation, was 6
years old at his last clinical evaluation and to our knowl-
edge remains alive. In addition, functional evaluation
showed evidence of a histocytochemical deficiency of
COX in S1 and S2, whereas this was reported as normal
in S3. Likewise, S2 has the most severe truncating muta-
tion and was observed to show the most severe mtDNA
depletion and most compromised mitochondrial respira-
tory chain activities in muscle.
The three families are linked by the common presenta-
tion of a disease phenotype consisting primarily of a fatal
mitochondrial encephalopathy and lactic acidosis, which
affected multiple members of each family in a pattern
consistent with the homozygous recessive FBXL4 muta-
tions identified. Intrauterine growth retardation, micro-
cephaly, and hypotonia were frequent nonspecific features
in the affected children from the families but are notThe American Journal of Human Geneuncommon findings in mitochon-
drial disease. On the other hand, the
craniofacial abnormalities, cataracts,
and developmental brain abnormal-
ities observed in several of thesechildren are indicative of a specific disease phenotype asso-
ciated with mutations in FBXL4 and with onset at an early
stage of fetal development. Classic myopathic, encephalo-
myopathic, and hepatocerebral presentations of mtDNA
depletion syndromes are not typically associated with
craniofacial or structural brain abnormalities, but early
development of cataracts has been observed in individuals
with reported mtDNA depletion resulting from mutations
in acylglycerol kinase (AGK [MIM 610345]).32 Interest-
ingly, the mtDNA depletion associated with AGK muta-
tions is thought to be indirect, secondary to an effect on
phospholipid metabolism and adenine nucleotide trans-
porter assembly in the inner mitochondrial membrane.33
In the absence of an obvious role for FBXL4 in the mtDNA
translation machinery, it is quite possible that a similarly
circuitous mechanism is responsible for the mtDNA deple-
tion observed in these cases.
FBXL4 is a member of a family of proteins that form a
component of the Skp1-Cullin-F-box (SCF) ubiquitin ligase
complex,34 which has been shown to have role in
phosphorylation-directed ubiquitination.35,36 Although
FBXL4 protein structure includes the canonical FBXL func-
tional domains, as with other orphan F-box proteins, the
precise function of this protein in human cells has not
been described. Crucially, we have shown that FBXL4
contains a mitochondrial localization signal and that the
protein colocalizes with mitochondria. Furthermore, fibro-
blasts from S1 and S2 show dramatic disturbance of the
mitochondrial network and significant redistribution of
nucleoids in addition to mtDNA depletion. It seems likely
that FBXL4 plays an important role in the maintenance of
mtDNA, although an exact mechanism for this function
remains undetermined. Further characterization of the
specific mitochondrial sublocalization of FBXL4 and the
interacting partners of this protein would begin to eluci-
date themechanism bywhich FBXL4mutations exert their
affect.
In conclusion, we report pathogenicmutations in FBXL4
and demonstrate a role for the encoded orphan F-box
protein in causing mitochondrial respiratory chaintics 93, 471–481, September 5, 2013 479
Figure 6. FBXL4 Gene Rescue Studies in
S1 and S2 Cells
Fibroblasts were transduced with either
GFP (black columns) or wild-type FBXL4
(gray columns) and compared to trans-
duced control fibroblasts.
(A–C) mtDNA copy number (A), complex
IV activity (B), and membrane potential
(C) were recovered to normal levels in S1
and S2 fibroblasts transfected with wild-
type FBXL4 but not GFP.
(D) FBXL4 mRNA levels were increased in
control (C) and S1 and S2 fibroblasts in-
fected with wild-type FBXL4 but not in
those infected with GFP. Transcript levels
are reported relative to GAPDH.
For all graphs, error bars indicate standard
deviation; ***p < 0.0001, **p < 0.01.deficiencies and depletion of mtDNA. Moreover, our study
exemplifies the power of combining genome-wide
sequencing with functional studies for the identification
and verification of pathogenic mutations in human genes
previously not associated with a disease phenotype.Acknowledgments
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